Project Grant R01HL180481
Award Date 8/15/25
Completion Date 5/31/29
Dollars Obligated $659K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Louisiana, USA
Similar Awards
- The National Heart, Lung, and Blood Institute (NHLBI) awarded a $425,505 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to Louisiana State University Health Sciences Center-Shreveport (LSU Health Sciences Center-Shreveport) to investigate the role of cell-specific Programmed Death-Ligand 1 (PD-L1) in cardiac pathophysiology following ischemic injury and cancer. The project aims to elucidate the specific mechanisms by which fibroblast-specific and myeloid...
- This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) provides $135,930 to the University of Connecticut Health Center to investigate the role of the TRPM7 ion channel in macrophage signaling and its impact on the development of atherosclerosis. The research aims to generate macrophage-specific TRPM7 deletion mice and subject them to a high-fat, Western diet atherosclerosis model to determine how in vivo TRPM7 deletion...
- The federal Project Grant award of $535,556.00 was provided by the National Heart Lung and Blood Institute under the Cardiovascular Diseases Research program (CFDA 93.837) to the University of Alabama at Birmingham (UAB). The funding will support a research project to investigate the role of a novel histone modification, H3T32 O-GlcNAc, in endothelial cell dysfunction and atherosclerosis. The 5-year project aims to elucidate the epigenetic features of this histone modification under...
- This federal Project Grant award of $1,565,823.00 was provided by the National Institute on Aging (NIA) under the Aging Research program (CFDA 93.866). The grant supports research to understand the biological mechanisms underlying the autophagy-lysosome system and its role in cellular quality control and aging processes. The principal investigator at Louisiana State University (LSU) aims to investigate how the dynamic transformation of lysosomes into expanded tubular networks can enhance...
- This federal Project Grant award, provided by the National Heart Lung and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research), supports research focused on understanding the role of the integrin receptor CD11B in atherosclerosis regression. The $752,709 grant awarded to the University of Maryland, Baltimore aims to investigate how macrophage-specific CD11B influences cholesterol efflux and inflammation, with the goal of developing new therapies to facilitate more efficient plaque...
- This Project Grant award of $646,106 from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) supports research by Tulane University to determine whether the induction of RECK, a regulator of proteinases, can prevent the development and progression of atherosclerosis. The research aims to 1) evaluate if RECK overexpression in smooth muscle cells attenuates atherosclerosis progression and promotes plaque stability, 2) study if RECK overexpression in...
- The National Heart, Lung, and Blood Institute (NHLBI) awarded a $771,750 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to the University of California, Los Angeles (UCLA) to investigate the role of macrophages in regulating cardiac muscle metabolism after myocardial infarction. The project aims to shed novel insights into how macrophages recruited to the infarcted heart disrupt cardiac muscle metabolism and lead to decreased NAD pools, which play a critical...
- The federal Project Grant award titled "REDUCING PLASMA CHOLESTEROL AND ATHEROSCLEROSIS USING MICRORNA-30C ANALOG C2" was provided by the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) to New York University's Long Island School of Medicine. The $1,364,153 award, granted on September 24, 2025, supports research to investigate the use of a synthetic microRNA-30c analog, C2, to reduce plasma cholesterol levels and atherosclerosis in mice. The...
- This $559,893 Project Grant award from the National Heart Lung and Blood Institute under the Cardiovascular Diseases Research program (CFDA 93.837) supports research to investigate the role of RSPO2 signaling through the LGR4 receptor in regulating arterial lymphangiogenesis, vascular smooth muscle cell phenotype, and atherosclerosis development. The project will be conducted by the University of Tennessee Health Science Center in Memphis, Tennessee over a 5-year period from January 2025 to...
- This $651,967 Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) aims to elucidate the role of cardiac tissue-resident macrophages in heart failure progression. The principal investigator at the Texas Heart Institute will conduct research over a 5-year period from August 2025 to May 2030 to determine how macrophage senescence contributes to cardiomyocyte dysfunction, inflammation, and impaired clearance of cellular debris in...